A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat

Life Sciences

Volumn 74, Issue 22, 2004, Pages 2749-2756

  Fries, Walter ^a,c   Mazzon, Emanuela ^a   Sturiale, Sergio ^a   Giofré, Maria R ^a   Lo Presti, Maria A ^a   Cuzzocrea, Salvatore ^a   Campo, Giuseppe M ^a   Caputi, Achille P ^a   Longo, Giuseppe ^a   Sturniolo, Giacomo C ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cloricromene; Experimental colitis; Heparin; MIP 2; Rat; Thromboembolism; TNF

Indexed keywords

ALCOHOL; CLORICROMEN; COUMARIN DERIVATIVE; DINITROBENZENESULFONIC ACID; MACROPHAGE INHIBTORY PEPTIDE 2; MACROPHAGE MIGRATION INHIBITION FACTOR; MYELOPEROXIDASE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSOCIATION; BLOOD CLOTTING; COLITIS; COLON MUCOSA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; EXPERIMENTAL MODEL; INTERMETHOD COMPARISON; MALE; MICROSCOPY; NONHUMAN; PARAMETER; REDUCTION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TISSUE INJURY; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; BENZENESULFONATES; BODY WEIGHT; CHROMONAR; COLITIS; COLON; INJECTIONS, SUBCUTANEOUS; INTESTINAL MUCOSA; MALE; MONOKINES; ORGAN SIZE; PEROXIDASE; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 12144290883     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.10.016     Document Type: Article

References (36)

1. Aporti F., Finesso M., Granata L. Effect of 8-monochloro-3-β- diethylaminoethyl-4-methyl-7-ethoxycarbonylmethoxycoumarin (AD6) on coronary circulation in the dog. Pharmacological Research Communications. 10(5):1978;467-477.
2. Appelberg R. Interferon-gamma and macrophage inflammatory proteins-1 and -2 are involved in the regulation of the T cell-dependent chronic neutrophilia of mice infected with mycobacteria. Clinical and Experimental Immunology. 89(2):1992;269-273.
3. Baggiolini M., Dewald B., Moser B. Interleukin-8 and related chemotactic cytokines: CXC and CC chemokines. Advances in Immunology. 55:1994;97-101.
4. Collins C.E., Cahill M.R., Newland A.C., Rampton D.S. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology. 106(4):1994;840-845.
5. Collins C.E., Rampton D.S. Platelets in inflammatory bowel disease - pathogenic role and therapeutic strategies. Alimentary Pharmacology & Therapeutics. 11(2):1997;237-247.
6. Corsini E., Lucchi L., Binaglia M., Viviani B., Bevilacqua C., Monastra G., Marinovich M., Galli C.L. Cloricromene, a semi-synthetic coumarin derivative, inhibits tumor necrosis factor-alpha production at a pre-transcriptional level. European Journal of Pharmacology. 418(3):2001;231-237.
7. Cuzzocrea S., Mazzon E., Bevilaqua C., Costantino G., Britti D., Mazzullo G., De Sarro A., Caputi A.P. Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats. British Journal of Pharmacology. 131(7):2000;1399-1407.
8. De Jong E., Porte R.J., Knot E.A.R., Verheijen J.H., Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa and faeces. Gut. 30(2):1989;188-194.
9. Dobosz M., Mionskowska L., Dobrowolski S., Dymecki D., Makarewicz W., Hrabowska M., Wajda Z. Is nitric oxide and heparin treament justified in inflammatory bowel disease? An experimental study. Scandinavian Journal of Clinical and Laboratory Investigation. 56(7):1996;657-663.
10. Driscoll K.E., Hassenbein D.G., Carter J., Poynter J., Asquith N., Grant R.A., Whitten J., Purdon M.P., Takigiku R. Macrophages inflammatory proteins 1 and 2: expression by rat alveolar macrophages, fibroblasts, and epithelial cells in rat lung after mineral dust exposure. American Journal of Respiratory Cell and Molecular Biology. 8(3):1993;311-316.
11. Edwards R.L., Levine J.B., Green R., Duffy M., Mathews E., Brande W., Ricjles F.R. Activation of blood coagulation in Crohn's disease. Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity. Gastroenterology. 92(2):1987;329-337.
12. Evans R.C., Wong V.S., Morris A.I., Rhodes J.M. Treatment of corticosteroid-resistant ulcerative colitis with heparin - a report of 16 cases. Alimentary Pharmacology & Therapeutics. 11(6):1997;1037-1040.
13. Folwaczny C., Wiebecke B., Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. The American Journal of Gastroenterology. 94(6):1999;1551-1555.
14. Fries W., Pagiaro E., Canova E., Carraro P., Gasparini G., Pomerri F., Martin A., Carlotto C., Mazzon E., Sturniolo G.C., Longo G. The effect of heparin on trinitrobenzene sulphonic acid-induced colitis in the rat. Alimentary Pharmacology & Therapeutics. 12(3):1998;229-236.
15. Gaffney P.R., Doyle C.T., Gaffney A., Hogan J., Hayes D.P., Annis P. Paradoxical response to heparin in ten patients with ulcerative colitis. The American Journal of Gastroenterology. 90(2):1995;220-223.
16. Groban L., Zvara D.A., Deal D.D., Vernon J.C., Flye C.W., Ma X.L., Vinten-Johansen J. Cloricromene reduces infarct size and alters postischaemic blood flow defects in dog myocardium. Clinical and Experimental Pharmacology & Physiology. 25(6):1998;417-423.
17. Hommes D.W., Peppelenbosch M.P., van Deventer S.J.H. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut. 52(2):2003;144-151.
18. Hudson M., Hutton R.A., Wakefield A.J., Sawyerr A.M., Pounder R.E. Evidence for activation of coagulation in Crohn's disease. Blood Coagulation & Fibrinolysis. 3(6):1992;773-778.
19. Kam L.Y., Targan S.R. TNF-alpha antagonists for the treatment of Crohn's disease. Expert Opinion on Pharmacotherapy. 1(4):2000;615-622.
20. Krawisz J.E., Sharon P., Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology. 87(6):1984;1344-1350.
21. Lam A., Borda I.T., Inwood M.J., Thomson S. Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology. 68(2):1975;245-251.
22. Lidbury P.S., Cirillo R., Vane J.R. Dissociation of the anti-ischaemic effects of cloricromene from its anti-platelet activity. British Journal of Pharmacology. 110(1):1993;275-280.
23. Orefice G., Grasso A., Fazio N., Del Vecchio G., Volpe G., Coppola M., D'Alessio A., Carrieri P.B. No effect of cloricromen on some coagulation parameters in patients with ischaemic cerebrovascular disease. The Journal of International Medical Research. 22(5):1994;287-291.
24. Prosdocimi M., Finesso M., Tessari F., Gorio A., Languino L.R., de Gaetano G., Dejana E. Inhibition by AD6 (8-monochloro-3-β- diethylaminoethyl-4-methyl-7-ethoxycarbonyl-methoxycoumarin) of platelet aggregation in dog stenosed artery. Thrombosis Research. 39(4):1985;399-409.
25. Prosdocimi M., Zatta A., Gorio A., Zanetti A., Dejana E. Action of AD6 (8-monochloro-3-β-diethylaminoethyl-4-methyl-7- ethoxycarbonylmethoxycoumarin) on human platelets in vitro. Naunyn Schmiedberg's Archives of Pharmacology. 332(3):1986;305-310.
26. Retsky J.E., Kraft S.C. The extraintestinal manifestations of inflammatory bowel disease. Kirsner J.B., Shorter R.G. Inflammatory Bowel Disease. 1995;474-491 Williams & Wilkins, Baltimore.
27. Ribaldi E., Mezzasoma A.M., Francescangeli E., Prosdocimi M., Nenci G.G., Goracci G., Gresele P. Inhibition of PAF synthesis by stimulated human polymophonuclear leucocytes with cloricromene, an inhibitor of phopholipase A2 activation. British Journal of Pharmacology. 118(6):1996;1351-1358.
28. Salas A., Sans M., Soriano A., Reverter J.C., Anderson D.C., Piqué J.M., Panes J. Heparin attenuates TNF-a induced inflammatory response through a CD11b dependent mechanism. Gut. 47(1):2000;88-96.
29. Schaufelberger H.D., Uhr M.R., Smith A.C., Logan R.P.H., Gordon-Smith E.C., Misiewicz J.J. Platelet activation in inflammatory bowel disease. Gut. 34:1993;S50.
30. Squadrito F., Prosdocimi M., Altavilla D., Zingarelli B., Caputi A.P. Cloricromene. Cardiovascular Drug Reviews. 9:1991;357-371.
31. Squadrito F., Altavilla D., Campo G.M., Calapai G., Ioculano M., Zingarelli B., Saitta A., Prosdocimi M., Caputi A.P. Cloricromene, a coumarine derivative, protects against lethal endotoxin shock in rats. European Journal of Pharmacology. 210(2):1992;107-113.
32. Thompson N.P., Wakefield A.J., Pounder R.E. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology. 108(4):1995;1011-1015.
33. Torkvist L., Thorlacius H., Sjoqvist U., Bohman L., Lapidus A., Flood L., Agren B., Raud J., Lofberg R. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Alimentary Pharmacology & Therapeutics. 13(10):1999;1323-1328.
34. Wallace J.L., Keenan C.M., Gale D., Shoupe T.S. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not realated to elevated leukotriene B4 synthesis. Gastroenterology. 102(1):1992;18-27.
35. Wallace J.L., Le T., Carter L., Appleyard C.B., Beck P.L. Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid. Journal of Pharmacological and Toxicological Methods. 33(4):1995;237-239.
36. Webberley M.J., Hart M.T., Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 34(2):1993;247-251.